Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorWashington University School of Medicine

About this trial

Polymyalgia rheumatica (PMR) is a condition that causes joint pain and stiffness, making it hard for people to do everyday tasks. Movement pattern training is a special, personalized rehabilitation program that aims to reduce pain by improving how people move during their daily activities. The investigators plan to test if it's possible to conduct a detailed study to find out how effective Movement pattern training is for people with PMR. The investigators will look at whether it helps them perform activities they want to do, reduce their use of certain medications, and strengthen their muscles. The investigators will also gather feedback from patients about their experience with Movement pattern training. This study will help us understand if carrying out a larger study on Movement pattern training's effectiveness is practical.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient reports a diagnosis or flare of polymyalgia rheumatica (PMR) < 5 months before the screening contact

Age ≥50 years at time of diagnosis

Presence of bilateral shoulder pain

Elevated acute phase reactants C-reactive protein (CRP) >10 milligram/Liter and/or Erythrocyte Sedimentation Rate (ESR) >30 millimeters/hour*

Disqualifiers

Diagnosis of fibromyalgia, neuropathic muscular disease, complex regional pain syndrome, or small fiber neuropathy

planned major surgical procedure during the study

Current active uncontrolled infection

Trial design

Design model

Parallel

Treatments tested in this trial

  • Movement Pattern Training (MoveTrain)

    Behavioral

    6 individualized treatment sessions over 10 weeks * Motivational interviewing to determine personal goals and strengthen motivation and commitment to change * Activity-specific training to practice modified motion during patient-specific tasks, defined as activities reported by each patient as pain-provoking * Home exercise program 3 times/week consisting of activities or exercises assigned in the supervised sessions * Patient's independence and adherence in performing home exercise program will be documented * Patients are encouraged to use modified motion during daily and physical activities * Based on patient performance, activity difficulty is progressed by increasing repetitions performed or increasing load or speed

  • Usual Care

    Other intervention

    * Basic education about polymyalgia rheumatica, benefits of physical activity * Patients will be encouraged to participate in physical activity as tolerated * Medication as prescribed by their physician

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: Usual CareActive comparator 1 intervention
Group B: Movement Pattern Training (MoveTrain)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Number of potential participants accessed.

The total number of people with Polymyalgia rheumatica (PMR) who were recruited each week

Time frame
7 months
2

Percent of eligible participants who were willing to be randomized

Percent of eligible participants are willing to be randomized during the study

Time frame
7 months

Secondary outcomes

1

Preliminary estimates of change in polymyalgia rheumatica impact scale (PMR-IS)

The change in polymyalgia rheumatica impact scale (PMR-IS), a self-report questionnaire specific to polymyalgia rheumatica, that represents the patients symptoms and functional ability.

Time frame
From enrollment to the end of treatment at 10 weeks
2

Preliminary estimates of change in physical activity

The change in physical activity as represented by the Stanford 7-DAy Physical Activity Recall survey

Time frame
From enrollment to the end of treatment at 10 weeks
3

Preliminary estimates of change in cumulative glucocorticoid dose

Change in cumulative glucocorticoid dose assessed by patient's self-report logs

Time frame
From enrollment to the end of treatment at 10 weeks
4

Preliminary estimates of change in muscle strength

change in muscle strength of the hips and shoulders, assessed using a hand dynamometer

Time frame
From enrollment to the end of treatment at 10 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.